Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price hoisted by Royal Bank Of Canada from $17.00 to $18.00 in a research report report published on Friday morning,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the biotechnology company’s stock.
Other equities analysts also recently issued reports about the company. William Blair upgraded Sarepta Therapeutics to a “hold” rating in a report on Wednesday, September 23rd. HC Wainwright reiterated a “sell” rating and issued a $5.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 5th. Wolfe Research upgraded shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research note on Thursday, July 9th. JPMorgan Chase & Co. decreased their target price on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, September 30th. Finally, Weiss Ratings downgraded shares of Sarepta Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, October 28th. Six analysts have rated the stock with a Buy rating, five have issued a Hold rating and seven have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $23.40.
Get Our Latest Research Report on SRPT
Sarepta Therapeutics Stock Performance
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.06. Sarepta Therapeutics had a negative return on equity of 0.20% and a negative net margin of 5.86%. The business had revenue of $381.35 million during the quarter, compared to analysts’ expectations of $352.20 million. During the same quarter in the previous year, the business earned ($0.13) earnings per share. The firm’s quarterly revenue was down 4.5% compared to the same quarter last year. On average, equities research analysts predict that Sarepta Therapeutics will post 3.27 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Sarepta Therapeutics
Several large investors have recently bought and sold shares of SRPT. BlackRock Inc. bought a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $341,339,000. First Trust Advisors LP raised its stake in Sarepta Therapeutics by 107.6% during the 1st quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock valued at $89,995,000 after buying an additional 2,143,211 shares during the last quarter. Bank of America Corp DE raised its stake in Sarepta Therapeutics by 26.6% during the 1st quarter. Bank of America Corp DE now owns 2,145,926 shares of the biotechnology company’s stock valued at $46,695,000 after buying an additional 450,336 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Sarepta Therapeutics by 43.6% during the 1st quarter. Renaissance Technologies LLC now owns 1,665,078 shares of the biotechnology company’s stock valued at $36,232,000 after buying an additional 505,500 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at $17,494,000. 86.68% of the stock is currently owned by institutional investors.
Key Sarepta Therapeutics News
Here are the key news stories impacting Sarepta Therapeutics this week:
- Positive Sentiment: Royal Bank of Canada raised its price target from $17 to $18, while maintaining a “sector perform” rating. Sarepta reported Q3 EPS of $0.13, above the $0.07 consensus cited by MarketBeat, and revenue of $381.35 million versus its $352.20 million estimate. MarketBeat earnings report
- Neutral Sentiment: Baird lowered its price target to $18. The target is close to the $17.82 share price cited in the report, suggesting limited upside at that level. StreetInsider report
- Negative Sentiment: Other earnings coverage said SRPT’s $0.13 EPS missed the Zacks consensus estimate of $0.37. Revenue was down 4.5% year over year, and reports said weaker Elevidys sales weighed on investor sentiment. Published earnings benchmarks differ, so the quarter’s result depends on which estimate is used. Zacks earnings coverage
- Negative Sentiment: A Sarepta-Hansa gene-therapy study has ended, raising questions for investors about the collaboration and its development prospects. The available report summary does not specify the study’s results or implications. TipRanks report
About Sarepta Therapeutics
Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs use RNA-based technologies, gene therapy and other genetic approaches to address the underlying causes of serious neuromuscular disorders.
The company’s primary focus is Duchenne muscular dystrophy (DMD), a progressive genetic disease that causes muscle weakness and loss of function. Sarepta markets Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen), RNA-based therapies designed to help certain patients produce a shortened but functional form of dystrophin.
Further Reading
- Five stocks we like better than Sarepta Therapeutics
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
